Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.

Sahil KhannaMaha AssiChristine LeeDavid YohoThomas LouieWhitfield KnappleHumberto AguilarJulia Garcia-DiazGary P WangScott M BerryJoe MarionXin SuTricia BraunLindy BanckePaul Feuerstadt

Published in: Drugs (2022)

NCT03244644; 9 August, 2017.

Keyphrases

double blind
phase iii
placebo controlled
clinical trial
open label
phase ii
clostridium difficile
study protocol
randomized controlled trial
nk cells